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Non-alcoholic fatty liver disease (NAFLD) is characterised by low circulating concentration of high-
density lipoprotein cholesterol (HDL-C) and raised triacylglycerol (TAG). Exercise reduces hepatic fat 
content, improves insulin resistance and increases clearance of very-low density lipoprotein-1 
(VLDL1). However, the effect of exercise on TAG and HDL-C metabolism is unknown. We randomised 
male participants to 16 weeks of supervised, moderate-intensity aerobic exercise (n=15) or 
conventional lifestyle advice (n=12). Apolipoprotein A-I (apoA-I) and VLDL-TAG and apolipoprotein B 
(apoB) kinetics were investigated using stable isotopes (1-13C-leucine and 1,1,2,3,3-2H5 glycerol) pre 
and post intervention. Participants underwent MRI/spectroscopy to assess changes in visceral fat. 
Results are mean ± standard deviation. 
At baseline, there were no differences between exercise and control groups for age (52.4±7.5 vs 
52.8±10.3 years), BMI (31.6±3.2 vs 31.7±3.6 kg/m2) and waist circumference (109.3±7.5 vs 
110.0±13.6 cm). Percentage liver fat was 23.8 (interquartile range 9.8–32.5%).  
Exercise reduced body weight (101.3±10.2 to 97.9±12.2 kg; P<0.001) and hepatic fat content (from 
19.6%, IQR 14.6-36.1% to 8.9% (4.4-17.8%); P=0.001) and increased the fraction HDL-C 
concentration (measured following ultracentrifugation) and apoA-I pool size with no change in the 
control group. However, plasma and VLDL1 TAG concentrations and HDL-apoA-I fractional catabolic 
rate (FCR) and production rate (PR) did not change significantly with exercise. Both at baseline (all 
participants), and after exercise, there was an inverse correlation between apoA-I pool size and VLDL 
TAG and apoB pool size. The modest effect of exercise on HDL metabolism may be explained by the 
lack of effect on plasma and VLDL1 TAG. 
 
 




The presence of non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of 
cardiovascular disease (CVD) (29). Whether NAFLD contributes to the development of CVD, or is an 
epiphenomenon, is unsettled (8). Adverse cardiovascular outcomes may be mediated via the 
proatherogenic plasma lipid profile that is seen with NAFLD. This includes a low concentration of 
high-density lipoprotein cholesterol (HDL-C), raised triacylglycerol (TAG) and raised small, dense low-
density lipoprotein (LDL) (2). Intravascular exchange of excess VLDL–TAG and HDL cholesteryl ester, 
mediated by cholesterol ester transfer protein (CETP), results in TAG accrual within the HDL particle. 
Lipolysis of HDL–TAG will then create smaller HDL particles which are more rapidly removed from 
the circulation than larger HDL, thereby reducing HDL concentration. Very-low density lipoprotein 
(VLDL) is secreted by the liver and comprises the large TAG-rich VLDL1 and the smaller, TAG-poor 
VLDL2. In individuals with abdominal obesity, dysfunctional VLDL1 metabolism is responsible for 
increased HDL apolipoprotein A-I (apoA-I) catabolism and low plasma HDL-C (11; 12; 19; 46; 48). 
In obese men, weight reduction of 5 to 10 kg with a low-fat diet can reduce hepatic VLDL-apoB 
secretion and decrease both HDL apoA-I catabolism and production (30; 36). Exercise training, with 
or without dietary intervention, is also an effective treatment for reducing liver fat in patients with 
NAFLD (4; 22). We have shown that 16 weeks supervised exercise training in men with NAFLD 
resulted in a decrease in intra-hepatocellular lipid (IHCL) content, and an increase in very-low density 
lipoprotein-1 triacylglycerol (VLDL1-TAG) and apolipoprotein B (apoB) fractional catabolic rates (FCR) 
(a measure of clearance) as well as increased VLDL1-apoB production rate (38). This suggested that 
exercise led to greater production of VLDL by the liver as well as greater clearance of the VLDL 
particle thereafter. Consequently, it is possible that the effect of exercise on VLDL kinetics that we 
observed will translate into effects on HDL kinetics. Thus far, only one study has reported on the 
effect of physical activity on HDL-apoA-I kinetics. (43; 48). Using exogenously labelled, iodinated, 
HDL it was found that HDL-apoA-I FCR decreased by 6% and HDL-apoA-I production rate (PR) 
increased by 13%, in response to one-year of exercise training in sedentary overweight participants. 
Hitherto, no studies have been made of the effect of exercise on HDL kinetics in NAFLD.  
We examined HDL kinetics from samples collected from our previous study of supervised exercise 
training in men with NAFLD. We hypothesised that exercise would increase the clearance of large, 
TAG-rich VLDL1 (VLDL1-TAG) thereby decreasing the clearance of apoA-I, and increasing the HDL 





The study design has been reported previously (11; 38). The study received NHS Research Ethics 
Committee approval and was registered at clinicaltrials.gov (NCT 01834300). All participants gave 
written informed consent. Males aged 40-65 years and body mass index (BMI) 27-40 kg/m2, with 
suspected NAFLD (referred for investigation with raised serum transaminases and/or indication of 
hepatic steatosis on ultrasound or liver biopsy) were eligible. 
Exclusion criteria were: NAFLD secondary to drug treatments, viral hepatitis, autoimmune hepatitis 
or primary biliary cirrhosis; history of type 2 diabetes mellitus, ischaemic heart disease; any 
contraindications to exercise; fasting plasma TAG >3.0 mmol/l or total cholesterol levels > 7.0 
mmol/l; current smokers; weekly alcohol consumption >21 units; contraindications to magnetic 
resonance imaging (MRI) such as cardiac pacemakers, metal implants; use of fibrates or beta-blocker 
medication. 
 
Participants were randomised to either exercise training or lifestyle advice. Participants were 
randomized to one of the two groups using a list generated by computer randomization, (Statistical 
Analysis System version 9.1, PROC PLAN software; SAS Institute). Supervised exercise training 
consisted of 16 weeks of gym-based or other modes of exercise to suit the participants’ lifestyle, at 
moderate intensity (40-60% heart rate reserve) for a minimum of 20 minutes initially (progressing 
towards 1 hour as the programme developed) 4 to 5 times per week. Participants received weekly 
supervision from an exercise trainer, usually in person (11; 38).   
The control group was advised to exercise and received standard lifestyle advice but with no further 
communication from the exercise trainer and no supervision. Both groups were asked to continue 
their usual diet. Participants made no dietary modifications - as confirmed by three-day food diaries 
collected immediately before and after the intervention and analysed for macronutrient intake. 
Metabolic measurements were made at Centre for Diabetes and Endocrine Research (CEDAR) 
centre, Royal Surrey County Hospital, Guildford, UK. Magnetic Resonance Imaging (MRI) and proton 
magnetic resonance spectroscopy (1H-MRS) measurements were made at the MRI unit, 





Body Composition and intra-hepatocellular fat measurements 
 
Height, weight and waist-to-hip ratio were measured before each metabolic study. All MRI studies 
were performed on a 1.5T multinuclear scanner (Achieva, Philips Medical Systems, Best, 
Netherlands) as previously described (42). Briefly, images were acquired using whole body axial T1 -
weighted spin echo sequence using a body coil and no respiratory gating (typical parameters: 
repetition time (TR) 560 ms; echo time (TE) 18 ms; slice thickness 10 mm; interslice gap 10 mm; flip 
angle 90 degrees; number of excitations 1). Subjects were positioned in the magnet in a prone 
position with their arms straight above their head and were scanned from their fingertips to their 
toes. Images were acquired as 9 equal stacks of 12 slices at the isocentre of the magnet. Images 
were analysed by Vardis (Vardis Group, London, UK) using SliceOmatic, (Tomovision, Montreal, 
Canada).  1H MRS of liver: Spectra were acquired using a PRESS sequence without water suppression 
(typical parameters: TR 1500 ms; TE 135 ms; voxel size 20x20x20 mm; flip angle 90 degrees, number 
of excitations 64). Transverse images of the liver were used to ensure positioning of the voxel, which 
was placed in an area of the liver avoiding the gall bladder, adipose tissue and main blood vessels. 
Spectra were analyzed using the AMARES (advanced method for accurate, robust, and efficient 
spectral fitting) algorithm included in the MRUI software package. Peak areas for all resonances 
were obtained and lipid resonances quantified with reference to water after correcting for T1 and 
T2.(41) 
 
Cardiorespiratory fitness assessment 
VO2max was performed on an electronically-braked bicycle ergometer (Lode; Excaliber Sport) with 
breath analyser (Medical Graphics). Heart rate was measured throughout. After 2-min warm up at 
50 W, resistance increased step-wise at 20 W/min until volitional exhaustion (7). 
 
Metabolic study 
The participants were asked to refrain from exercise activity for 48 hours prior to the two metabolic 
studies (baseline visit and at 16 weeks) and to fast for 13 hours beforehand.  Upon arrival, patients 
were weighed, and an intravenous cannula was placed in a superficial vein for administration of 
isotopes and another in the contralateral arm for blood sampling. Two basal blood samples were 
taken for the determination of basal enrichments of leucine and glycerol in VLDL1, VLDL2 and HDL 
6 
 
fractions; and for enrichment of plasma glycerol and α ketoisocaproic acid (KIC). A primed (1 mg/kg) 
infusion of 1-13C-leucine (1 mg/kg/h, for 9 hours) and a bolus of [1,1,2,3,3-2H5 glycerol (75 µmol/kg) 
were then administered at 0 min.  Blood samples were taken from 0-540 min, as we reported 
previously (38). The plasma samples for ultracentrifugation were stored at 4oC until analysis on the 
following day. All other plasma samples were kept at -80oC until analysis. 
 
Analytical methods 
After removal of VLDL1 (sf >60) and VLDL2 (sf 20-60) by sequential centrifugation, a mixture of 
intermediate-density (IDL) and LDL was removed at an adjusted density of 1.063 kg/L at 147000g for 
20 hours using sodium bromide. The HDL fraction was isolated at a density of 1.21 kg/L following 
ultracentrifugation for 24 hours at 218000g, 4oC (Beckman Coulter Optima LE80-K ultracentrifuge 
using a Type 50.4 Ti rotor (High Wycombe, UK). The HDL fraction thus collected was adjusted for 
volume (2 mL) using saline and stored at -80oC for further analysis of HDL-C and apoA-I 
concentration and enrichment of HDL-apoA-I. Fractionated and unfractionated plasma HDL-C 
concentration was measured with Cobas MIRA (Roche, Welwyn Garden City, UK). 
 
Isolation of VLDL1 and VLDL2 TAG and apoB as well as measurements of enrichment and 
concentration of 2H5-glycerol in TAG and 1-13C-leucine in apoB have been explained in detail in a 
previous publication on this study (38). 
ApoA-I from the HDL fraction (400ul) was precipitated in 8 mL of ice-cold methanol:diethyl ether 
(V:V), mixed vigorously and centrifuged at 1792 g for 20 min at 4oC. The precipitate was further 
extracted with ice-cold diethyl ether and centrifuged as before. The precipitate was dried and 
dissolved in sample buffer, pH 6.8, in preparation for polyacrylamide gel electrophoresis (PAGE). 
Samples were loaded on polyacrylamide gels (10% resolving &1% stacking) and ran overnight as 
previously reported (27). Following PAGE, the bands for ApoA-I were visualised by silver stain (Bio-
Rad, USA), excised from the gel and hydrolysed in the presence of 6M HCl at 120oC for 24 h. The free 
amino acids were further purified by cation exchange chromatography using (Dowax AG-50W-X8 
100-200 mesh). 
Isotopic enrichment of 13C leucine from apoA-I and apoB were measured in oxazolinone derivative 
applied on gas chromatography mass spectroscopy GCMS (GCMS; GC system, Agilent 5973C) in 
negative CI mode with methane as reagent gas (38). Ions monitored were 209 m/z 12C and 210 m/z 
13C leucine, tracer/tracee ratios were calculated for the time course of the study. 
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Isotopic enrichment of plasma α-ketoisocaproic acid (KIC), a measure of intracellular leucine 
enrichment for apoB and apoA-I synthesis, was measured by GCMS (38). Plasma glucose, NEFA and 
TAG, total cholesterol, and lipoprotein fraction cholesterol and TAG were measured with enzymatic 
reagents with Cobas Mira analyser (38). ApoA-I concentration in the HDL fraction was analysed by 
immunoturbidimetric method (Horiba ABX, France) with a Cobas MIRA analyser (Horiba ABX, France) 
inter assay cv 3.17% and intra-assay cv 5.5%. Insulin and plasma adiponectin were measured by 
radioimmunoassay purchased from Millipore Ltd, MA, USA. The intra-assay cv was 6% and 5% 
respectively. Fetuin A was measured by ELISA (Epitope Diagnostics), with intra-assay cv 4.8%. Irisin 
was measured by ELISA (Phoenix Pharmaceuticals), with intra-assay cv 4.1%. 
 
Data analysis 
The kinetics of HDL-apoA-I, production rate (PR) and fractional clearance rate (FCR) were calculated 
using tracer:tracee ratio (TTR) of apoA-I between 2 and 9 hours. This is the period when the 
enrichment curves of apoA-I are linear, the enrichment of α-KIC is at steady state and apoA-I 
concentration is unchanged. TTR was calculated as tracer/tracee in samples after the infusion minus 
tracer/tracee at baseline. 
During fasting the apoA-I concentration is at steady state and fractional secretion rate (FSR) is equal 
to the FCR (27).  
FCR (pools/day) = (rate of increase of apoA-I TTR per min/ α-KIC TTR at steady state) x 24 x 60. 
The production rate (PR) was calculated from the FCR and the pool size as follows: apoA-I PR 
(mg/kg/day) = FCR x HDL-apo-I pool size. 
Apo-A-I pool size was calculated using concentration (mean of apoA-1 concentration in four 
samples) and plasma volume (PV) and body weight (BW). ApoA-I pool size (mg/kg) = HDL-apoA-I 
concentration x PV / BW. 
PV was calculated as PV (mL) = 1578 x body surface area (m2) (32).  
Body surface area (BSA) was calculated using BW in kg (DuBois) as follows: 
BSA (m2) = (BW 0.245) x (height x 0.725) x 0.007184 
Kinetics of apoB and TAG in VLDL1 and VLDL2 fractions were calculated using SAAM II model as 
reported in an earlier publication (38). Homeostasis model assessments of insulin resistance 





This is a post-hoc analysis of a previously reported randomised controlled trial powered to detect a 
20% within-group reduction in VLDL-apoB production with 80% power at the 5% level (38). 
Statistical analysis of the data was performed using SPSS for Windows v25 (IBM Corp. Armonk, NY). 
Results are means ± standard deviation unless stated otherwise. Data were tested for normality 
using Shapiro-Wilk. Basal comparisons were performed using Student’s independent t test 
(parametric) or Mann-Whitney U (non-parametric). The differences between baseline and 16 weeks 
were compared within groups using paired t-tests or Wilcoxon (nonparametric) and between groups 
using student’s t test for parametric data and Mann-Whitney U test for nonparametric data. 
Correlations between metabolic variables were determined using Spearman’s rho correlation 





Subject characteristics  
We have reported on the characteristics of the study population previously (11; 38). At baseline 
there were no differences between exercise and control groups for age (52.4 ±.7.5 vs 52.8 ± 10.3 
years; P=0.99), BMI (31.6 ± 3.2 vs 31.7 ± 3.6 kg/m2; P=0.956) and waist circumference (109.3 ± 7.5 vs 
110.0 ± 13.6 cm; P=0.872). Percentage liver fat was 23.8 (IQR 9.8 – 32.5%). 
In the exercise training group there was a significant within-group change in body weight (101.3 ± 
10.2 to 97.9 ± 12.2 kg; P<0.001). This equated to loss of 3.6% of their baseline weight; n=13 of the 
exercise group achieved at least modest (≤3%) weight loss and n=6 achieved >3% weight loss. The 
exercise group also showed significant change in: BMI (31.6 ± 3.2 to 30.5 ± 3.7 kg/m2; P=0.001), 
fasting glucose (6.0 ± 0.8 to 5.8 ± 0.7mmol/L; P=0.005), HOMA2 S% (32.5 ± 11.0 to 45.6 ± 18.9%; 
P=0.002), VO2max (25.5 ± 4.1 to 33.0 ± 5.8 mL/kg/min; P<0.001), IHCL content (median 19.6%, IQR 
14.6-36.1) to 8.9% (4.4-17.8); P=0.001 and alanine aminotransferase (ALT), from 51.1 ± 20.6 to 36.8 
± 20.0 iU/L; P=0.013. However, no effect was seen with exercise on adiponectin (5560 ± 2636 ng/mL 
to 5901 ± 2806 ng/mL; P=0.226), irisin (138.8 ± 25.6 to 131.1 ± 22.4 ng/mL; P=0.187) or Fetuin A 
(483.9 ± 82.8 to 471.0 ± 97.2 µg/mL; P=0.402). 
 
By contrast, in the control group, significant within-group changes were only seen in glucose (5.9 ± 
0.5 to 5.6 ± 0.3mmol/L; P=0.016) and ALT concentrations (40.9 ± 21.5 to 31.1 ± 16.3 iU/L; P=0.041). 
Consequently, there were significant between-group changes in weight (P<0.001), BMI (P=0.016), 
waist circumference (P=0.026), insulin sensitivity (P=0.003) and VO2max (P<0.001). 
 
Lipid profile 
As we have reported (38), baseline lipid profiles were similar in the exercise training and control 
groups. Plasma TAG, VLDL1-TAG (Table 1), NEFA and total cholesterol concentrations did not change 
within, or between, groups. Plasma LDL-C decreased in the exercise training group (from 3.8 ± 0.5 to 
3.3 ± 0.6mmol/L; P=0.03). The fraction HDL-C decreased with exercise (Table 1) but there was no 
change in plasma HDL-C, measured without ultracentrifugation, (from 1.01 ± 0.22 to 1.03 ± 0.23 
mmol/L; P=0.234). The ratio of total cholesterol to fractional HDL-C was also significantly reduced 
after the exercise training. There were no significant changes in the control group after the 16 weeks 





HDL-apoA-I pool-size increased significantly after 16 weeks exercise training (P=0.046) (Table 2) with 
no change in the control group. However, between-group changes in HDL-apoA-I pool-size were not 
different. There were no within- or between-group changes in HDL-apoA-I FCR or HDL-apoA-I PR 
(Table 2). 
 
Relationship between HDL-apoA-I, VLDL1-apoB and VLDL2-apoB at baseline 
At baseline, HDL-apoA-I FCR (but not HDL-apo-A-I PR) correlated positively with ALT, aspartate 
aminotransferase (AST), and Fetuin A and correlated negatively with fraction HDL-C (rho -0.423; 
P=0.028) and adiponectin (rho -0.547; P=0.003) (Table 3). 
HDL-apo-A-I PR positively correlated with Fetuin A and negatively with VLDL2 apoB PR (rho -0.417; 
P=0.03) and negatively with irisin (rho -0.539; P=0.004).  
Baseline HDL-apoA-I pool-size (n=27) correlated inversely with total VLDL-TAG pool-size (rho -0.533; 
P=0.005; Figure 1), VLDL1-TAG pool-size (rho -0.542; P=0.004) and VLDL2-TAG pool-size (rho -0.385; 
P=0.047) and correlated positively with VLDL1-TAG FCR (rho 0.431; P=0.026). 
HDL-apoA-I pool-size was also inversely correlated with total VLDL apoB pool-size (rho -0.464; 
P=0.015) and with VLDL2 apo-B pool-size (rho -0.497; P=0.009).  HDL-apoA-I pool-size correlated 
positively with VLDL1 and VLDL2 apoB FCR (rho 0.416; P=0.032 and rho 0.474; P=0.013 respectively) 
(Table 3). 
 
Correlations with delta changes post intervention from baseline in lipid kinetics. 
We have previously reported that exercise increased VLDL1 apoB FCR from 7.18 ± 0.57 to 10.93 ± 
1.49 pools/day compared with 10.91 ± 1.76 to 8.88 ± 1.06 pools/day in control (P=0.01 between 
groups).  Furthermore, that VLDL1-TAG FCR changed from 8.25 ± 1.07 to 9.80 ± 1.51 pools/day with 
exercise versus 9.09 ± 0.80 to 8.62 ± 1.02 pools/day in controls (P=0.06 between groups). (38) 
 
Correlation between delta changes post exercise intervention from baseline for HDL-apoA-I and 
VLDL1- and VLDL2-TAG and apoB and other variables are tabulated in Table 4. The Δ HDL-apoA-I pool-
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size inversely correlated with Δ VLDL-apoB pool-size (rho -0.729; P=0.002), Δ VLDL1-TAG pool-size 
(rho -0.650; P=0.009) and Δ total VLDL-TAG pool-size (rho -0.586; P=0.022). The Δ HDL-apoA-I pool-
size correlated positively with Δ VLDL1-apoB FCR (rho=0.596, p=0.019) and with VLDL1-TAG FCR 
(rho=0.555; P=0.049). These relationships were not seen in the control group (Table 5). 
The Δ body weight significantly correlated with Δ apoB PR (rho -0.560; P = 0.002). All other 
correlations between Δ baseline to post-intervention, for HDL-apoA-I PR, HDL-apo-A-I FCR, body 
weight, HDL-C:apoA-I ratio, IHCL and total visceral fat with other variables are tabulated for all 




We report, for the first time, the effect of an exercise intervention on HDL kinetics in patients with 
NAFLD. Although there was an increase in fraction HDL-C concentration and apoA-I pool size, HDL-
apoA-I FCR and PR did not change significantly. Both at baseline, and after exercise, there was an 
inverse correlation between apoA-I pool size and VLDL TAG and apoB pool size which confirms the 
well documented inverse relationship between HDL and VLDL metabolism (45). Similarly, at baseline 
there were also striking positive relationships between apoA-I pool size and the clearance of VLDL1 
TAG and apoB. 
There is evidence that VLDL1 and VLDL2 are independently regulated (28) and that exercise primarily 
affects VLDL1 kinetics (16). As we reported previously, 16 weeks of exercise increased VLDL1-TAG and 
apoB FCR in these subjects (38) and the current study shows that the change in these measurements 
(with exercise) negatively correlated with the change in apoA-I pool size.  
Exercise had no effect on VLDL2 TAG and apoB FCR and thus perhaps, not surprisingly, there was no 
correlation between the change in these measurements with exercise and apoA-I pool size. The 
modest effect of exercise on HDL metabolism may be explained by the lack of effect on plasma and 
VLDL1 TAG concentration. Although IHCL was reduced, it was not normalised and the liver continued 
to export excessive amounts of TAG as measured by VLDL-TAG production rate. (38) A longer 
duration of exercise may be required to reduce IHCL to normal and achieve a significant change in 
HDL metabolism.  
 
To date, the only published study of the effect of exercise training on HDL-apoA-I kinetics was by 
Zmuda et al (48). They showed that in overweight participants, with baseline HDL-C < 40mg/dL (1.03 
mmol/L), a one-year exercise intervention reduced body weight by 1.2 kg and increased HDL apoA-I 
and HDL-C concentrations. Underlying this was a reduction in apoA-I clearance as well as an increase 
in apoA-I production. Murine models suggest that exercise increases the expression of proteins 
involved in cholesterol efflux, including liver X receptor-α (LXRα) (21) and ATP-binding cassette A1 
(ABCA1) (15). This could have the effect of increasing hepatic clearance of HDL. However, little-to-no 
effect of exercise on HDL parameters was seen when baseline HDL-C > 44mg/dL (1.14 mmol/L) (48) 
and so these observations may represent regression to the mean. Furthermore, the methodology 
used in that paper comprised exogenously radio-labelled HDL which was then re-injected, and 
plasma kinetics measured over 10 days. This methodology has inherent uncertainty as to whether 
the tracer has identical metabolic properties to the tracee (35). 
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From studies of knock-out mice, it has been suggested that HDL formation regulates VLDL-TAG 
production, resulting in an inverse relationship between plasma HDL-C and TAG concentration (31).  
However, our data rather suggests that VLDL clearance lowers VLDL TAG, thereby reducing the 
intravascular exchange of TAG between VLDL and HDL - which in turn may increase HDL apoA-I pool 
size. This concept is supported by the study of Verges et al (46). 
There are conflicting data for the effect of exercise training on HDL-C concentration in NAFLD, with 
either no effect (11; 39), or improvement (33). In T2DM, increased HDL-C concentration has been 
reported in response to aerobic exercise training after 12-26 weeks (1; 3; 25). However, 12-weeks of 
resistance training had no effect on HDL-C levels (20). The diverse prescription of duration, 
frequency and intensity of exercise will all contribute to the heterogeneity of response to the effect 
of exercise on lipoproteins (18; 24). 
Whereas exercise, without weight loss, produces a 20–30% relative reduction in intrahepatic lipid 
(18), it has been suggested that for an effect of exercise to be seen on HDL-C, at least modest weight 
loss (≥3%) is required (40). In our study, exercise led to 3.6% weight loss and improvement in 
HOMA2-IR and fraction HDL-C. However, we did not observe a correlation between the degree of 
weight loss and change in HDL production or clearance. 
In recent years, HDL functionality has been considered a better predictor of cardiovascular disease 
risk than HDL-C concentration (37). NAFLD is associated with reduced HDL efflux (13) and exercise is 
associated with increased HDL particle size (17; 40; 44) and cholesterol-efflux capacity (23). We used 
the fraction HDL-C : apoA-I ratio as a surrogate marker for particle size but found no change with 
exercise. 
HDL-apoA-I FCR correlated with ALT and AST levels at baseline (although not with IHCL). It is unclear 
whether the magnitude of intra-hepatic fat impacts on the hepatocytes through higher hepatic 
lipase (HL) activity and hence increased clearance of HDL. In this study we did not measure post-
heparin lipase activity. Previous studies have shown the activity of hepatic lipase to be increased in 
obese men (26; 34) and women (6; 9) with high intra-abdominal fat levels.   
The present study has several strengths. This was a randomized controlled trial in which the exercise 
group was supervised by research staff and had a distinct intensity of exercise comprising an aerobic 
dose consistent with physical activity recommendations. We allowed at least 48 hours from the final 
exercise session before metabolic studies thereby removing any acute effect of exercise on HDL 
metabolism (14). HDL-C concentration was measured following isolation of the HDL-C fraction by 
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ultracentrifugation. This is more precise and accurate than kit assays (47). In addition, we utilized 
endogenous stable isotope labelling to assess HDL metabolism in vivo.  
This study was not an evaluation of the effects of exercise independent of its effect on body weight. 
For this reason, the results observed might also be achieved by dieting. However, exercise has a 
particular benefit in reducing hepatic fat (4; 22), which was evident in our study. The exercise 
programme was free-living and so energy output was not quantified. However, all participants 
received weekly support from a trainer to maintain commitment to the protocol. As there are 
pronounced differences in fat metabolism between sexes (5), this study was limited to male 
participants.  
In conclusion, a 16-week exercise programme reduced body weight and hepatic fat content but 
without significant changes to HDL kinetics. The strong relationship between the change in VLDL-
TAG pool size and change in HDL apoA-I pool size, in response to exercise, confirms that VLDL-TAG is 



















































0.76 ± 0.12 0.80 ± 0.11 0.140 1.24 ± 0.56 1.06 ± 0.12 0.314 0.068 
TC : fraction 
HDL-C ratio 
 
6.6 ± 2.4 5.4 ± 2.0 0.0035 7.0 ± 3.0 6.3 ± 2.3 0.320 0.573 
 
Fraction HDL-C : 
apoA-I ratio 
1.06 ± 0.17 1.14 ± 0.19 0.186 1.16 ± 0.57 1.06 ± 0.12 0.546 0.307 
























apoA-I: apolipoprotein A-I, NEFA: non-esterified fatty acids, TC: total cholesterol, TAG: 





 Table 2 - HDL-apoA-I kinetics (mean ± SD) 















































4.4 ± 1.1 4.4 ± 1.2 0.984 3.2 ± 1.3 3.5 ± 1.5 0.573 0.648 
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Table 3- Correlations between HDL-apoA-I and VLDL kinetics at baseline (n=27).  
VLDL: Very low density lipoprotein,  LDL: low-density lipoprotein,  HDL: high density 













    
VLDL1-apoB pool size 
(mg) 
rho 0.230 
P = 0.249 
rho -0.006 
P = 0.977 
rho -0.364 
P = 0.062 
VLDL2-apoB pool size 
(mg) 
rho -0.074 
P = 0.713 
rho -0.344  
P = 0.079 
rho -0.497 
P = 0.009 
Total VLDL apoB pool 
size (mg) 
rho 0.157 
P = 0.435 
rho -0.121 
P = 0.547 
rho -0.464 




P = 0.323 
rho 0.037 
P = 0.855 
rho 0.416 




P = 0.024 
rho -0.177 
P = 0.378 
rho 0.474 




P = 0.969 
rho -0.125 
P = 0.535 
rho -0.110 




P = 0.031 
rho -0.417 
 P = 0.030 
rho 0.033 
P = 0.871 
Total VLDL-apoB PR 
(mg/kg/day) 
rho -0.134 
P = 0.506 
rho -0.173 
P = 0.390 
rho 0.004 
P = 0.984 
VLDL1-TAG pool size 
(µmol/kg) 
rho 0.133 
P = 0.508 
rho -0.129 
P = 0.520 
rho -0.542 
P = 0.004 
VLDL2-TAG pool size 
(µmol/kg) 
rho 0.213 
P = 0.285  
rho 0.002 
P = 0.990 
rho -0.385 
P = 0.047 
Total VLDL-TAG pool 
(µmol/kg) 
rho 0.253 
P = 0.204 
rho -0.090 
P = 0.655 
rho -0.533 
P = 0.005 
VLDL1 TAG PR 
(mg/kg/day) 
rho 0.003 
P = 0.987 
rho -0.205  
P = 0.305 
rho -0.373 




P = 0.624 
rho -0.051 
P = 0.800 
rho -0.212 




P = 0.116 
rho -0.116  
P = 0.564 
rho 0.431  








P = 0.345 
rho -0.169 
P = 0.399 
rho 0.056 
P = 0.782 
Ratio of fraction HDL 
to ApoA-I 
rho 0.162 
P = 0.180 
rho 0.143 
P = 0.47 
rho -0.091 
P = 0.652 
Plasma TAG (mmol/L) 
rho 0.309 
P = 0.168 
rho 0.079 
P = 0.696 
rho -0.378 






P = 0.413 
rho 0.346 




P = 0.028 
rho -0.061 
P = 0.763 
rho 0.546  
P = 0.004 
ALT (iU/L) 
rho 0.505 
P = 0.007 
rho 0.325 
P = 0.098 
rho -0.235 
P = 0.238 
AST (iU/L) 
rho 0.442 
P = 0.021 
rho 0.375 
P = 0.054 
rho 0.012 
P = 0.953 
IHCL (%) 
rho 0.357 
P = 0.068 
rho 0.364  
P = 0.062 
rho -0.054  
P = 0.788 
Adiponectin (ng/mL) 
rho -0.547 
P = 0.003 
rho -0.338 
p = 0.084 
rho 0.308 
P = 0.118 
Irisin (ng/mL) 
rho -0.256 
P = 0.197 
rho -0.539 
p = 0.004 
rho -0.386 
P = 0.047 
Fetuin A (µg/mL) 
0.583  
P = 0.001 
rho 0.552 
p = 0.003 
rho 0.029 
P = 0.886 
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Table 4- Correlations between changes in HDL kinetics and changes in VLDL kinetics at 16 









    
VLDL1-apoB pool size (mg) 
rho 0.132 
P = 0.639 
rho -0.025 
P = 0.930 
rho -0.507 
P = 0.054 
VLDL2-apoB pool size (mg) 
rho -0.207 
P = 0.459 
rho -0.368 
P = 0.177 
rho -0.232 
P = 0.405 
Total VLDL-apoB pool size 
(mg) 
rho -0.011 
P = 0.970 
rho -0.332 
P = 0.226 
rho -0.729  
P = 0.002 
VLDL1-apoB FCR (pools/day) 
rho -0.164 
P = 0.558 
rho -0.054 
P = 0.850 
rho 0.596 
P = 0.019 
VLDL2-apoB FCR (pools/day) 
rho 0.275 
P = 0.321 
rho 0.350 
P = 0.201 
rho 0.104 
P = 0.713 
VLDL1-apoB PR (mg/kg/day) 
rho 0.036 
P = 0.889 
rho 0.021 
P = 0.940 
rho 0.382 
P = 0.160 
VLDL2-apoB PR (mg/kg/day) 
rho -0.046 
P = 0.869 
rho -0.189 
P = 0.499 
rho -0.196 
P= 0.483 
Total VLDL-apoB PR 
(mg/kg/day) 
rho -0.089 
P = 0.752 
rho -0.096 
P = 0.732 
rho 0.429 
P = 0.111 
VLDL1-TAG pool size 
(µmol/kg) 
rho 0.050 
P = 0.860 
rho -0.161 
P = 0.567 
rho -0.650 
P = 0.009 
VLDL2-TAG pool size 
(µmol/kg) 
rho -0.186 
P = 0.508 
rho -0.168 
P = 0.550 
rho 0.061 
P = 0.830 
Total VLDL-TAG pool size 
(µmol/kg) 
rho -0.025 
P = 0.930 
rho -0.218 
P = 0.435 
rho -0.586 
P = 0.022 
VLDL1-TAG PR (mg/kg/day) rho 0.137 rho 0.071 rho 0.007 
21 
 
P = 0.655 P = 0.817 P = 0.100 
VLDL2-TAG PR (mg/kg/day) 
rho -0.559 
P = 0.059 
rho -0.573 
P = 0.051 
rho 0.217 
P = 0.499 
VLDL1-TAG FCR (pools/day) 
rho 0.027 
P = 0.929 
rho 0.154 
P = 0.616 
rho 0.555 
P = 0.049 
VLDL2-TAG FCR (pools/day) 
rho -0.441 
P =0.152 
rho -0.622  
P = 0.031 
rho -0.224 
P = 0.484 
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Table 5 - Correlations between changes in HDL kinetics with changes in VLDL kinetics at 16 









VLDL1-apoB pool size (mg) 
rho -0.497 
P = 0.104 
rho -0.350 
P = 0.265 
rho -0.608 
P = 0.036 
VLDL2-apoB pool size (mg) 
rho -0.573 
P = 0.051 
rho -0.357 
P = 0.255 
rho -0.622 
P = 0.031 
VLDL-apoB pool size (mg) 
rho -0.536 
P = 0.073 
rho -0.515 
P = 0.087 
rho -0.722 
P = 0.008 
VLDL1-TAG pool size (µmol/kg) 
rho 0.091 
P = 0.779 
rho -0.217 
P = 0.499 
rho -0.098 
P = 0.762 
Total VLDL-TAG pool size 
(µmol/kg) 
rho 0.105 
P = 0.746 
rho 0.056 
P = 0.863 
rho 0.084 
P = 0.795 
VLDL1-apoB FCR (pools/day) 
rho 0.042 
P = 0.897 
rho 0.196 
P = 0.542 
rho 0.217 
P = 0.499 
VLDL1-apoB PR (mg/kg/day) 
rho -0.035 
P = 0.914 
rho -0.021 
P = 0.948 
rho -0.007 
P = 0.983 
Total VLDL-apoB PR 
(mg/kg/day) 
rho 0.063 
P = 0.846 
rho 0.007 
P = 0.983 
rho 0.056 
P = 0.863 
VLDL1-TAG FCR (pools/day) 
rho -0.266 
P = 0.404 
rho 0.126 
P = 0.697 
rho -0.042 
P = 0.897 
VLDL2-TAG FCR (pools/day) 
rho -0.224 
P = 0.484 
rho 0.385 
P = 0.217 
rho 0.028 
P = 0.931 
VLDL1-TAG PR (mg/kg/day) 
rho -0.126 
P = 0.697 
rho 0.140 
P = 0.665 
rho 0.021 
P = 0.948 
VLDL2-TAG PR (mg/kg/day) 
rho -0.336 
P = 0.286 
rho 0.098 
P = 0.762 
rho -0.168 






Appendix 1- Correlation between changes in HDL kinetics, weight, HDL-c : apoA-1 ratio, IHCL and total visceral fat with changes in VLDL and 





Fraction HDL-C  












Total visceral fat 




P = 0.683 
rho - 0.429 
P = 0.026 
rho -0.024 
P = 0.905 
rho -0.208 
P = 0.297 
rho 0.019 
P = 0.925 
rho -0.263 
P = 0.186 
rho 0.209 




P = 0.263 
rho - 0.409 
P = 0.034 
rho -0.194 
P = 0.332 
rho -0.366 
P = 0.061 
rho 0.481 
P = 0.011 
rho 0.355 
P = 0.069 
rho 0.013 




P = 0.724 
rho -0.627 
P < 0.001 
rho -0.159 
P = 0.428 
rho -0.428 
P = 0.026 
rho 0.327 
P = 0.096 
rho -0.104 
P = 0.606 
rho 0.151 




P = 0.415 
rho 0.413 




P = 0.804 
rho -0.540 
P = 0.004 
rho -0.133 
P = 0.508 
rho -0.491 




P = 0.995 
rho 0.069 
P = 0.732 
rho 0.342 
P = 0.081 
rho 0.334 
P = 0.089 
rho -0.313 
P = 0.112 
rho -0.143 
P = 0.475 
rho -0.172 




P = 0.271 
rho 0.251 




P = 0.901 
rho -0.622 
P < 0.001 
rho -0.423 
P = 0.028 
rho -0.461 




P = 0.058 
rho -0.271 
P = 0.171 
rho 0.138 
P = 0.493 
rho -0.072 
P = 0.721 
rho 0.133 
P = 0.507 
rho 0.107 
P = 0.596 
rho -0.188 




P = 0.080 
rho 0.277 
P = 0.162 
rho -0.047 
P = 0.815 
rho -0.045 
P = 0.825 
rho -0.560 
P = 0.002 
rho -0.409 
P = 0.034 
rho -0.531 
P = 0.004 
VLDL1 TAG PR 
(mg/kg/day) 
rho -0.125 
P = 0.550 
rho 0.068 
P = 0.745 
rho 0.082 
P = 0.696 
rho 0.053 
P = 0.801 
rho 0.129 
P = 0.540 
rho 0.138 
P = 0.509 
rho -0.065 
P = 0.756 
VLDL2 TAG PR rho -0.063 rho -0.201 rho -0.106 rho = -0.248 rho 0.193 rho 0.359 rho 0.117 
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(mg/kg/day) P = 0.768 P = 0.347 P = 0.622 P = 0.243 P = 0.367 P = 0.085 P = 0.585 




P = 0.412 
rho 0.052 
P = 0.804 
rho 0.158 
P = 0.449 
rho 0.133 
P = 0.526 
rho 0.179 
P = 0.391 
rho 0.175 
P = 0.404 
rho -0.045 
P = 0.832 




P = 0.667 
rho -0.250 
P = 0.209 
rho 0.017 
P = 0.934 
rho -0.013 
P = 0.947 
rho 0.655 
P < 0.001 
rho 0.399 
P = 0.039 
rho 0.393 
P = 0.043 
VLDL1 TAG pool 
size (µmol/kg) 
rho 0.150 
P = 0.455 
rho -0.225 
P = 0.260 
rho -0.033 
P = 0.869 
rho -0.042 
P = 0.835 
rho 0.584 
P = 0.001 
rho 0.286 
P = 0.148 
rho 0.405 
P = 0.036 
VLDL2 TAG pool 
size (µmol/kg) 
rho -0.217 
P = 0.278 
rho -0.262 
P = 0.187 
rho -0.081 
P = 0.689 
rho -0.180 
p = 0.369 
rho 0.529 
P = 0.005 
rho 0.451 
P = 0.018 
rho 0.221 
P = 0.268 
VLDL1 TAG FCR 
(pools/day) 
rho -0.112 
P = 0.596 
rho 0.250 
P = 0.228 
rho 0.118 
P = 0.575 
rho 0.118 
P = 0.575 
rho -0.430 
P = 0.032 
rho -0.089 
P = 0.671 
rho -0.483 
P = 0.014 
VLDL2 TAG FCR 
(pools/day) 
rho 0.03 
P = 0.888 
rho -0.150 
P = 0.483 
rho -0.063 
P = 0.771 
rho -0.259 
P = 0.221 
rho -0.431 
P = 0.036 
rho -0.341 
P = 0.103 
rho -0.137 





P = 0.828 
rho -0.199 
P = 0.320 
rho -0.033 
P = 0.870 
rho -0.188 
P = 0.347 
rho -0.020 
P = 0.923 
rho 0.321 






P = 0.817 
rho 0.428 
P = 0.026 
rho -0.287 
P = 0.146 
rho -0.040 
P = 0.842 
rho -0.188 







P = 0.498 
rho 0.070 
P = 0.729 
rho 0.090 






   
rho -0.093 
P = 0.645 
rho 0.129 
P = 0.522 
rho 0.020 
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Figure 1. Correlation of ApoA-I pool size with VLDL-TG pool size at baseline (n=27) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
 
 
 
 
